Cutting-Edge Cancer Therapies Lead the Way Into a Transformative Year
Insider Purchase: Chief Financial Officer of $IBIO (IBIO) Buys 9,191 Shares
Press Release: IBio Announces New Investments From Board Members and Officers
Express News | Ibio Announces New Investments From Board Members and Officers
Express News | Ibio Discovers Novel Antibody Targeting Activin E in Collaboration With Astralbio
IBio Discovers Novel Antibody Targeting Activin E in Collaboration With AstralBio
Express News | Ibio Inc: Astralbio Eligible for Development & Commercialization Milestone Payments Totaling up to $28 Mln
Express News | Ibio Inc: Plans to Enter Into Clinical Investigation in Obesity and Cardiometabolic Disorders in 2026
IBio Expands Obesity Program With $750K Upfront Payment and $28M AstralBio Partnership
IBio Expands Cardiometabolic and Obesity Program With Anti-Myostatin Antibody Discovered Using Its Proprietary Platform, In-Licensed From AstralBio
IBio Inc. Stock Rises Tuesday, Outperforms Market
IBio Analyst Ratings
Lucid Capital Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6
IBio Names David Arkowitz and António Parada to Its Board >IBIO
Express News | Ibio Strengthens Board With Appointment of Two New Independent Directors
Press Release: IBio Strengthens Board With Appointment of Two New Independent Directors
Trump Nominates Marty Makary For FDA Commissioner
IBio GAAP EPS of -$0.46 In-line
iBio Inc | 8-K: iBio Reports Fiscal First Quarter 202 5 Financial Results
Express News | IBio Q1 EPS $(0.46) Beats $(0.48) Estimate